Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why

Yahoo FinanceNov 25 12:00 ET

Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?

Simply Wall StNov 22 09:46 ET

Allogene Therapeutics Announces Participation in December Investor Conferences

GlobeNewswireNov 19 08:30 ET

Allogene Therapeutics Presents Data for ALLO-329 in Autoimmune Disease

TipRanksNov 18 08:45 ET

Express News | Allogene Therapeutics Highlights Presentation Of ALLO-329 Preclinical Data At American College of Rheumatology Convergence 2024

BenzingaNov 18 08:39 ET

Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Cuts Target Price to $9

Moomoo NewsNov 14 07:31 ET · Ratings